Handok

Handok Net Debt per Share

The Net Debt per Share of Handok (002390.KS) as of Nov 4, 2026 is 5,849.32 KRW. In the previous year, Net Debt per Share was 10,383.55 KRW — a change of -43.67% (lower).

Net Debt per Share

5,849.32KRW

YoY

-43.67%

Last updated:

Net Debt per Share of Handok is 2025 5,849.32 KRW. Net Debt per Share of Handok was 2024 10,383.55 KRW. It decreases by -43.67% lower compared to the previous year.

The Handok Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2018
11,510.65 KRW
Jan 1, 2019
15,523.01 KRW
Jan 1, 2020
11,105.25 KRW
Jan 1, 2021
10,083.63 KRW
Jan 1, 2022
13,418.81 KRW
Jan 1, 2023
8,993.37 KRW
Jan 1, 2024
10,383.55 KRW
Jan 1, 2025
5,849.32 KRW
The Handok Net Debt per Share history
YEARNet Debt per ShareYoY
5,849.32KRW-43.67%
10,383.55KRW+15.46%
8,993.37KRW-32.98%
13,418.81KRW+33.08%
10,083.63KRW-9.20%
11,105.25KRW-28.46%
15,523.01KRW+34.86%
11,510.65KRW-16.16%
13,728.63KRW+12.72%
12,179.01KRW+8.15%
11,260.76KRW+8.35%
10,393.22KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Handok Stock analysis

What does Handok do? Handok, Inc. generates revenue through the manufacture and sale of pharmaceutical products including Amaryl for diabetes, Tritace for hypertension and cardiovascular diseases, Teveten and Triapin for hypertension, Munobal for hypertension and stenocardia, Ketas for cerebral circulation issues, and Lasix for hypertension and edema. The company also sells over-the-counter pharmaceuticals, healthcare products, medical devices, diagnostic reagents, and vaccines. Additionally, Handok, Inc. earns income from real estate rental services. Its products target healthcare providers, hospitals, and pharmacies as key buyers within the pharmaceutical and healthcare sectors. The firm's product portfolio includes branded medications such as Amaryl, Tritace, Teveten, Triapin, Munobal, Ketas, and Lasix, which are distributed to medical professionals and retail pharmacies. Over-the-counter products and healthcare items are sold directly to consumers through retail channels. Medical devices and diagnostic reagents are supplied to healthcare facilities and laboratories. Vaccines are distributed to public health institutions and clinics. Handok, Inc. serves multiple market segments including diabetes management, cardiovascular care, hypertension treatment, and neurological health through its diverse product range. The company's real estate rental business supports its financial operations by providing steady income streams from leased properties. Key buyers include healthcare providers, pharmacies, hospitals, and public health institutions that purchase its branded pharmaceuticals and medical solutions. Handok is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Handok stock

Net Debt per Share of Handok is 5,849.32 KRW in 2025.

Net Debt per Share of Handok changed from 10,383.55 KRW to 5,849.32 KRW, representing a -43.67% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share Handok since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Handok

All Key Metrics — Handok